Finally, although the presence of the V617F mutation in the Janus kinase 2 gene (JAK2V617F) has been identified in 6.6% of CVT patients [12], only 3.8% had a diagnosis of myeloproliferative neoplasm (MPN) throughout their lives [13]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.